-
Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers Gut (IF 24.5) Pub Date : 2024-04-23 BMJ Publishing Group Ltd and British Society of Gastroenterology
Carotenuto P, Fassan M, Pandolfo R, et al . Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut 2017;66:1268-1277. The legend of Figure …
-
Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis Gut (IF 24.5) Pub Date : 2024-04-23 Stefano Crippa, Giovanni Marchegiani, Giulio Belfiori, Paola Vittoria Maria Rancoita, Tommaso Pollini, Anna Burelli, Laura Apadula, Maria Giovanna Scarale, Davide Socci, Marco Biancotto, Giuseppe Vanella, Paolo Giorgio Arcidiacono, Gabriele Capurso, Roberto Salvia, Massimo Falconi
Objective Cost-effectiveness of surveillance for branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) is debated. We combined different categories of risks of IPMN progression and of IPMN-unrelated mortality to improve surveillance strategies. Design Retrospective analysis of 926 presumed BD-IPMNs lacking worrisome features (WFs)/high-risk stigmata (HRS) under surveillance. Charlson Comorbidity
-
Spatial genomics: mapping human steatotic liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-23 Kylie P. Matchett, Jasmin Paris, Sarah A. Teichmann, Neil C. Henderson
-
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 L. A. A. P. Derikx, F. Hoentjen
LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.17993
-
Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Ayesha Shah, Gerald Holtmann
LINKED CONTENTThis article is linked to Ricciuto et al paper. To view this article, visit https://doi.org/10.1111/apt.17936
-
Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Luciano Revelli, Melisa Dirchwolf
LINKED CONTENTThis article is linked to Mücke et al paper. To view this article, visit https://doi.org/10.1111/apt.17899
-
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W. Leong
SummaryBackgroundThe expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real‐world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial
-
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 María José García, Javier P. Gisbert, María Chaparro
LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.17973
-
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
SummaryBackgroundRecently, a panel of multi‐society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction‐associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD).AimsWe compared the impact of SLD, subtype of SLD, MAFLD and NAFLD on all‐cause and cause‐specific mortality.MethodsA total of 7811 individuals in the third National
-
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Nina Løn, Sara Engel, Anders Damholt, Anja Wellejus, Filip K. Knop
LINKED CONTENTThis article is linked to Løn et al papers. To view these articles, visit https://doi.org/10.1111/apt.17817 and https://doi.org/10.1111/apt.17984
-
Letter: Bif195 for aspirin‐induced gastric mucosal damage—More to do in further research Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Yuxin Wang, Wenwan Peng, Mingguo Dong
LINKED CONTENTThis article is linked to Løn et al papers. To view these articles, visit https://doi.org/10.1111/apt.17817 and https://doi.org/10.1111/apt.18002
-
Editorial: Adequate protein intake is more crucial than the profile of amino acids intake for sarcopenia prevention during the earlier stages of liver cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Meropi D. Kontogianni
LINKED CONTENTThis article is linked to Hey et al paper. To view this article, visit https://doi.org/10.1111/apt.17917
-
Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Leya Nedumannil, Mustafa Mohamedrashed, Siddharth Sood, Diana Lewis
LINKED CONTENTThis article is linked to Vaishnav et al papers. To view these articles, visit https://doi.org/10.1111/apt.17868 and https://doi.org/10.1111/apt.17982
-
Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Hirokazu Takahashi, Miwa Kawanaka, Yoshio Sumida, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki
SummaryAimsA multi‐stakeholder consensus has proposed MASLD (metabolic dysfunction‐associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid‐term mortality of patients with biopsy‐proven MASLD in Japan.MethodsWe enrolled 1349 patients with biopsy‐proven MASLD. The observational period was 8010 person years. We evaluated independent factors associated
-
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Carolin V. Schneider, Kai Markus Schneider, Rohit Loomba
LINKED CONTENTThis article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and https://doi.org/10.1111/apt.17986
-
-
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long‐term adverse outcomes in Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Agnès Fernández‐Clotet, Ingrid Ordás, Maria Carme Masamunt, Berta Caballol, Sonia Rodríguez, Marta Gallego, Rebeca Barastegui, Anny Carolina Saavedra, Julián Panés, Elena Ricart, Jordi Rimola
SummaryBackground and AimsMagnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long‐term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long‐term outcomes.MethodsPatients
-
Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Elton Dajti, Susana G. Rodrigues
LINKED CONTENTThis article is linked to Elsaid et al paper. To view this article, visit https://doi.org/10.1111/apt.17925
-
Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Dominik Bettinger, Robert Thimme, Lukas Sturm
LINKED CONTENTThis article is linked to Yoon et al paper. To view this article, visit https://doi.org/10.1111/apt.17909
-
Editorial: Crystalising the burden of steatotic liver disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Luis Calzadilla Bertot, Leon A. Adams
LINKED CONTENTThis article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and https://doi.org/10.1111/apt.17992
-
Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-22 Stephanie A. Vuijk, Maria M. E. Jongsma, Britt M. Hoeven, Maarten A. Cozijnsen, Merel van Pieterson, Tim G. J. de Meij, Obbe F. Norbruis, Michael Groeneweg, Victorien M. Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F. van Rheenen, Michiel P. van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J. Poley, Johanna C. Escher, Lissy de Ridder
SummaryBackgroundData on cost‐effectiveness of first‐line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed.AimTo investigate the cost‐effectiveness of first‐line infliximab compared to conventional treatment in children with moderate‐to‐severe Crohn's disease.MethodsWe
-
Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Paul Henderson
-
Editorial: Foretelling the future—Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Siri A. Urquhart, Joel G. Fletcher, David H. Bruining
-
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Enrico N. De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
-
Editorial: High qHBsAg—is it a good or bad signal? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Beom Kyung Kim
-
Editorial: Peering through the fog—New tools to assess neurocognitive symptoms in coeliac disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Javier A. Villafuerte Gálvez, Daniel A. Leffler
-
Editorial: Enriching our understanding of MASLD through representation of under‐reported populations Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Niharika Samala, Eduardo Vilar‐Gomez
-
Letter: Risks of proton pump inhibitor treatment in cirrhotic patients Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Jiamei Wang, Feng Wen, Jian Zhao
-
Letter: The enigma of angiotensin receptor blocker‐associated enteropathy Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Mustafa Mohamedrashed, Leya Nedumannil, Mayur Garg
-
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Shinji Okabayashi, Taku Kobayashi
-
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Basile Njei, Joseph K. Lim
-
Editorial: Can dietary gluten restriction improve hepatic steatosis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Hariklia Kranidioti, Melanie Deutsch
-
Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Jian Wang, Yifan Pan, Ye Xiong, Chao Wu, Rui Huang
-
Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 John E. Eaton, Sudhakar K. Venkatesh
-
Hypoxia-inducible factor-1α mediates reflux-induced epithelial-mesenchymal plasticity in Barrett’s oesophagus patients Gut (IF 24.5) Pub Date : 2024-04-19 Qiuyang Zhang, Kerry B Dunbar, Robert D Odze, Agoston T Agoston, Xuan Wang, Tianhong Su, Anh D Nguyen, Xi Zhang, Stuart Jon Spechler, Rhonda F Souza
Introduction Epithelial-mesenchymal plasticity (EMP), the process through which epithelial cells acquire mesenchymal features, is needed for wound repair but also might contribute to cancer initiation. Earlier, in vitro studies showed that Barrett’s cells exposed to acidic bile salt solutions (ABS) develop EMP. Now, we have (1) induced reflux oesophagitis in Barrett’s oesophagus (BO) patients by stopping
-
Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management Gut (IF 24.5) Pub Date : 2024-04-18 Luca Fabris, Jonathan Pol
In the realm of cholangiocarcinoma (CCA), a malignancy often presenting with biliary stenosis, the clinical need to re-establish duct patency offers a unique opportunity to profile bile content, facilitating the identification of potential diagnostic and prognostic biomarkers. Various studies have explored the significance of biochemically distinct molecules in the bile of patients with CCA by comparing
-
Proton pump inhibitors increase the risk of carbapenem-resistant Enterobacteriaceae colonization by facilitating the transfer of antibiotic resistance genes among bacteria in the gut microbiome Gut Microbes (IF 12.2) Pub Date : 2024-04-18 Imchang Lee, Jae-Won Jo, Heung-Jeong Woo, Ki Tae Suk, Seung Soon Lee, Bong-Soo Kim
Carbapenem-resistant Enterobacteriaceae (CRE) pose a global health threat; however, there is still limited understanding of the risk factors and underlying mechanisms of CRE colonization in the gut...
-
The gut microbe pair of Oribacterium sp. GMB0313 and Ruminococcus sp. GMB0270 confers complete protection against SARS-CoV-2 infection by activating CD8+ T cell-mediated immunity Gut Microbes (IF 12.2) Pub Date : 2024-04-18 Mingda Wang, Enkhchimeg Lkhagva, Sura Kim, Chongkai Zhai, Md Minarul Islam, Hyeon J. Kim, Seong-Tshool Hong
Despite the potential protective role of the gut microbiome against COVID-19, specific microbes conferring resistance to COVID-19 have not yet been identified. In this work, we aimed to identify an...
-
Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-18 David Beaton, Linda Sharp, Liya Lu, Nigel Trudgill, Mo Thoufeeq, Brian Nicholson, Peter Rogers, James Docherty, Anna Jenkins, A. John Morris, Thomas Rösch, Matthew Rutter
SummaryBackgroundThe value of lower gastrointestinal endoscopy (LGIE; colonoscopy or sigmoidoscopy) relates to its ability to detect clinically relevant findings, predominantly cancers, preneoplastic polyps or inflammatory bowel disease. There are concerns that many LGIEs are performed on low‐risk patients with limited benefit.AimsTo determine the diagnostic outcomes of LGIE for common symptoms.MethodsWe
-
Sialic acid-based probiotic intervention in lactating mothers improves the neonatal gut microbiota and immune responses by regulating sialylated milk oligosaccharide synthesis via the gut–breast axis Gut Microbes (IF 12.2) Pub Date : 2024-04-17 Yushuang Wang, Binqi Rui, Xiaolei Ze, Yujia Liu, Da Yu, Yinhui Liu, Zhi Li, Yu Xi, Xixi Ning, Zengjie Lei, Jieli Yuan, Liang Li, Xuguang Zhang, Wenzhe Li, Yanjie Deng, Jingyu Yan, Ming Li
Human milk oligosaccharides (HMOs) are vital milk carbohydrates that help promote the microbiota-dependent growth and immunity of infants. Sialic acid (SA) is a crucial component of sialylated milk...
-
A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome Gut Microbes (IF 12.2) Pub Date : 2024-04-17 S Srivastava, U Basak, M Naghibi, V Vijayakumar, R Parihar, J Patel, PS Jadon, A Pandit, RR Dargad, S Khanna, S Kumar, R Day
To determine the efficacy of the probiotic Bifidobacterium longum CECT 7347 (ES1) and postbiotic heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in improving symptom severity in adults with ...
-
Effects of Prevotella copri on insulin, gut microbiota and bile acids Gut Microbes (IF 12.2) Pub Date : 2024-04-16 Jiatai Gong, Qianjin Zhang, Ruizhi Hu, Xizi Yang, Chengkun Fang, Liping Yao, Jing Lv, Long Wang, Mingkun Shi, Wentao Zhang, Siqi Ma, Hongkun Xiang, Hongfu Zhang, De-Xing Hou, Yulong Yin, Jianhua He, Lijun Peng, Shusong Wu
Obesity is becoming a major global health problem in children that can cause diseases such as type 2 diabetes and metabolic disorders, which are closely related to the gut microbiota. However, the ...
-
Dietary fiber guar gum-induced shift in gut microbiota metabolism and intestinal immune activity enhances susceptibility to colonic inflammation Gut Microbes (IF 12.2) Pub Date : 2024-04-17 Devendra Paudel, Divek V. T. Nair, Sangshan Tian, Fuhua Hao, Umesh K. Goand, Grace Joseph, Eleni Prodes, Zhi Chai, Chloé E.M. Robert, Benoit Chassaing, Andrew D. Patterson, Vishal Singh
With an increasing interest in dietary fibers (DFs) to promote intestinal health and the growth of beneficial gut bacteria, there is a continued rise in the incorporation of refined DFs in processe...
-
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults Gut (IF 24.5) Pub Date : 2024-04-16 Abid Suddle, Helen Reeves, Richard Hubner, Aileen Marshall, Ian Rowe, Dina Tiniakos, Stefan Hubscher, Mark Callaway, Dinesh Sharma, Teik Choon See, Maria Hawkins, Suzanne Ford-Dunn, Sarah Selemani, Tim Meyer
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term
-
Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-17 Maria Mironova, Harish Gopalakrishna, Gracia Maria Viana Rodriguez, Nehna Abdul Majeed, Asif A. Hitawala, Ivan J. Fuss, Jenna R. E. Bergerson, Alison J. Faust, Jacqueline M. Laurin, Jaha Norman‐Wheeler, Shani Scott, Julian Hercun, Bernadette Redd, David E. Kleiner, Christopher Koh, Theo Heller
SummaryBackgroundNon‐cirrhotic portal hypertension (NCPH) is a spectrum of liver diseases, including porto‐sinusoidal vascular disorder, with portal hypertension (PH) in the absence of cirrhosis. The natural history and diagnostic approach to NCPH are not well understood.AimWe aimed to evaluate disease progression and outcomes in NCPH.MethodsPatients with or at risk for NCPH were enrolled in a single
-
A crucial Fusobacterium nucleatum clade in colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-16 Katrina Ray
A distinct Fusobacterium nucleatum clade, Fna C2, that is dominant in the human colorectal cancer (CRC) niche has been identified in a new study published in Nature. Importantly, in mice, Fna C2 treatment led to increased numbers of large intestinal adenomas and altered metabolite profiles. The findings illuminate the crucial connection between a bacterial subspecies and human colon cancer and provide
-
Artificial intelligence in liver cancer — new tools for research and patient management Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-16 Julien Calderaro, Laura Žigutytė, Daniel Truhn, Ariel Jaffe, Jakob Nikolas Kather
-
Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer Gut (IF 24.5) Pub Date : 2024-04-15 Feifei Zhang, Varun Sahu, Ke Peng, Yichen Wang, Tianxia Li, Pratyusha Bala, Daulet Aitymbayev, Pranshu Sahgal, Antje Schaefer, Channing J Der, Sandra Ryeom, Sam Yoon, Nilay Sethi, Adam J Bass, Haisheng Zhang
Objective Genomic studies of gastric cancer have identified highly recurrent genomic alterations impacting RHO signalling, especially in the diffuse gastric cancer (DGC) histological subtype. Among these alterations are interchromosomal translations leading to the fusion of the adhesion protein CLDN18 and RHO regulator ARHGAP26. It remains unclear how these fusion constructs impact the activity of
-
Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients Gut (IF 24.5) Pub Date : 2024-04-15 Christina S Thornton, Barbara J Waddell, Stephen E Congly, Julianna Svishchuk, Ranjani Somayaji, Linda Fatovich, Debra Isaac, Karen Doucette, Kevin Fonseca, Steven J Drews, Jamie Borlang, Carla Osiowy, Michael D Parkins
Objectives In high-income countries hepatitis E virus (HEV) is an uncommonly diagnosed porcine-derived zoonoses. After identifying disproportionate chronic HEV infections in persons with cystic fibrosis (pwCF) postlung transplant, we sought to understand its epidemiology and potential drivers. Design All pwCF post-transplant attending our regional CF centre were screened for HEV. HEV prevalence was
-
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis Gut (IF 24.5) Pub Date : 2024-04-15 Jinxia Liu, Jane MacNaughtan, Annarein J C Kerbert, Theo Portlock, Javier Martínez Gonzalez, Yi Jin, Frederick Clasen, Abeba Habtesion, Huoyan Ji, Qin Jin, Alexandra Phillips, Francesco De Chiara, Ganesh Ingavle, Cesar Jimenez, Giacomo Zaccherini, Katherine Husi, Miguel Angel Rodriguez Gandia, Paul Cordero, Junpei Soeda, Lynda McConaghy, Jude Oben, Karen Church, Jia V Li, Haifeng Wu, Aarti Jalan, Pere
Objective Targeting bacterial translocation in cirrhosis is limited to antibiotics with risk of antimicrobial resistance. This study explored the therapeutic potential of a non-absorbable, gut-restricted, engineered carbon bead adsorbent, Yaq-001 in models of cirrhosis and acute-on-chronic liver failure (ACLF) and, its safety and tolerability in a clinical trial in cirrhosis. Design Performance of
-
Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-14 Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun-Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk-Kyun Yang, Byong Duk Ye
-
A high fiber diet or supplementation with Lactococcus lactis subspecies cremoris to pregnant mice confers protection against intestinal injury in adult offspring Gut Microbes (IF 12.2) Pub Date : 2024-04-15 Maria E. Barbian, Joshua A. Owens, Crystal R. Naudin, Patricia Denning, Ravi M. Patel, Rheinallt M. Jones
The diet during pregnancy, or antenatal diet, influences the offspring’s intestinal health. We previously showed that antenatal butyrate supplementation reduces injury in adult murine offspring wit...
-
Crohn's disease after surgery: Changes in post‐operative management strategies over time and their impact on long‐term re‐operation rate—A retrospective multicentre real‐world study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-15 Annalisa Aratari, Maria Lia Scribano, Daniela Pugliese, Valentina Baccolini, Fabiola De Biasio, Serena Verna, Chiara Morretta, Stefano Festa, Alessandro Armuzzi, Claudio Papi
-
EUS-guided gallbladder drainage in acute cholecystitis: response to letter to the editor Gut (IF 24.5) Pub Date : 2024-04-12 Ji Young Bang, Juan Pablo Arnoletti, Andrew Wagner, Shyam Varadarajulu
We thank the authors for their interest in our report on endoscopic ultrasound-guided gallbladder drainage (EUS-GBD).1 Management of gallbladder disease is not within the sole domain of gastroenterologists. It includes surgeons and interventional radiologists. When guidelines are developed without multidisciplinary consensus, problems can occur as reported in our series.2 The distinction between never-surgery
-
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines Gut (IF 24.5) Pub Date : 2024-04-12 Benjamin H Mullish, Blair Merrick, Mohammed Nabil Quraishi, Aggie Bak, Christopher A Green, David J Moore, Robert J Porter, Ngozi T Elumogo, Jonathan P Segal, Naveen Sharma, Belinda Marsh, Graziella Kontkowski, Susan E Manzoor, Ailsa L Hart, Christopher Settle, Josbert J Keller, Peter Hawkey, Tariq H Iqbal, Simon D Goldenberg, Horace R T Williams
The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition
-
Lactococcus lactis HkyuLL 10 suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase Gut (IF 24.5) Pub Date : 2024-04-10 Anthony Chin Yang Su, Xiao Ding, Harry Cheuk Hay Lau, Xing Kang, Qing Li, Xueliang Wang, Yali Liu, Lanping Jiang, Yinghong Lu, Weixin Liu, Yanqiang Ding, Alvin Ho-Kwan Cheung, Ka Fai To, Jun Yu
Objective Probiotic Lactococcus lactis is known to confer health benefits to humans. Here, we aimed to investigate the role of L. lactis in colorectal cancer (CRC). Design L. lactis abundance was evaluated in patients with CRC (n=489) and healthy individuals (n=536). L. lactis was isolated from healthy human stools with verification by whole genome sequencing. The effect of L. lactis on CRC tumourigenesis
-
Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-10 Mikkel Malham, Sabine Jansson, Helene Ingels, Marianne Hørby Jørgensen, Naja Hulvej Rod, Vibeke Wewer, Matthew P. Fox
-
Cognitive behavioral and mindfulness with daily exercise intervention is associated with changes in intestinal microbial taxa and systemic inflammation in patients with Crohn’s disease Gut Microbes (IF 12.2) Pub Date : 2024-04-09 Ilan K, Motro Y, Nemirovsky A, Schwartz D, Goren G, Sergienko R, Greenberg D, Slonim-Nevo V, Sarid O, Friger M, Regev S, Odes S, Moran-Gilad J, Monsonego A
Crohn’s disease (CD) is a chronic inflammatory bowel disease associated with psychological distress and intestinal microbial changes. Here, we examined whether a 3-month period of Cognitive Behavio...
-
New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation Gut Microbes (IF 12.2) Pub Date : 2024-04-09 Tomaž Bratkovič, Abida Zahirović, Maruša Bizjak, Maja Rupnik, Borut Štrukelj, Aleš Berlec
Clostridioides difficile causes a range of debilitating intestinal symptoms that may be fatal. It is particularly problematic as a hospital-acquired infection, causing significant costs to the heal...
-
Multi-strain probiotics during pregnancy in women with obesity influence infant gut microbiome development: results from a randomized, double-blind placebo-controlled study Gut Microbes (IF 12.2) Pub Date : 2024-04-09 Sofie Ingdam Halkjær, Malene Refslund Danielsen, Victoria E. de Knegt, Lee O’Brien Andersen, Christen Rune Stensvold, Henrik Vedel Nielsen, Hengameh Chloé Mirsepasi-Lauridsen, Karen Angeliki Krogfelt, Dina Cortes, Andreas Munk Petersen
Probiotics have been described to influence host health and prevent the risk of obesity by gut microbiome (GM) modulation. In a randomized double-blinded placebo-controlled feasibility study, we in...